The developmentally regulated GTP-binding protein-2 (DRG2) is a novel subclass of GTPbinding proteins. Many functional characteristics of osteoclasts (OC) are associated with small GTPases. We hypothesized that DRG2 affects bone mass via modulating OC activity. Using DRG2 transgenic mice, we investigated the role of DRG2 in bone remodeling. DRG2 overexpression caused a decrease in bone mass and an increase in the number and activity of OC in vivo. DRG2 overexpression increased fusion, spreading, survival, and resorption activity of OC in vitro. Downregulation of DRG2 by siRNA decreased fusion, spreading, and survival of OC, supporting the observations found in DRG2 transgenic OC. Transgenic mature OCs were larger, with actin rings and higher ERK, Akt, Rac1 and Rho activities than wild-type OCs. Inhibition of these proteins abolished the effects of DRG2 on formation of large OCs with actin rings, implying that DRG2 affects cytoskeleton reorganization in a Rac1/Rho/ERK/Akt-dependent manner. In summary, DRG2 is associated with survival and cytoskeleton organization of OC under influence of macrophage colony-stimulating factor, and its overexpression leads to elevated bone resorptive activity of OC, resulting in bone loss. DRG2; osteoclast; fusion; spreading; bone resorption BONE UNDERGOES DYNAMIC REMODELING, and maintenance of bone mass and integrity requires a precise balance between bone resorption by osteoclasts (OC) and bone formation by osteoblasts. In osteoporosis, resorption exceeds formation, whereas osteopetrosis is due to defective OC formation and function. OC differentiation depends on at least two factors derived from stromal cells/osteoblasts: macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-B ligand (RANKL) (3, 12). During differentiation, OCs become multinucleated by fusion, which plays a critical role in bone resorption (13). To actively resorb bone, OC forms an actin ring that is a complex molecular attachment structure that seals off an extracellular compartment located between the cell and resorbing bone (5). By virtue of tight sealing, the extracellular compartment is characterized by maintaining a low pH and enriching lysosomal enzymes that are required for digestion of the bone matrix.
BONE UNDERGOES DYNAMIC REMODELING, and maintenance of bone mass and integrity requires a precise balance between bone resorption by osteoclasts (OC) and bone formation by osteoblasts. In osteoporosis, resorption exceeds formation, whereas osteopetrosis is due to defective OC formation and function. OC differentiation depends on at least two factors derived from stromal cells/osteoblasts: macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-B ligand (RANKL) (3, 12) . During differentiation, OCs become multinucleated by fusion, which plays a critical role in bone resorption (13) . To actively resorb bone, OC forms an actin ring that is a complex molecular attachment structure that seals off an extracellular compartment located between the cell and resorbing bone (5) . By virtue of tight sealing, the extracellular compartment is characterized by maintaining a low pH and enriching lysosomal enzymes that are required for digestion of the bone matrix.
Many OC properties that are necessary for efficient bone resorption, such as actin ring formation, fusion, and cell survival, depend on the activity of small GTPases (6, 15, 16, 36) . The Rho family of GTPases plays a critical role in actin organization, with RhoA, Rac1, Cdc42, and RhoU being responsible for cytoskeletal organization and the polarization of OCs (6, 15, 36) . The ARF GTPase family, known to regulate membrane trafficking and actin dynamics, is responsible for the regulation of the OC cytoskeleton and formation of the sealing zone (11) . Decrease in Rac2 impairs migration and fusion required for OC and results in bone defects found in Shwachman-Diamond syndrome (24) . The activity of Rac1 (9) and Ras (4) is essential for OC survival. Although several small GTPases have been shown to participate in OC activity, much remains to be discovered about the functions and interactions of the molecules associated with OC differentiation and bone resorption.
The developmentally regulated GTP-binding proteins (DRG) are novel members of the GTPase superfamily (23) . The DRG subfamily members, DRG1 and DRG2, are broadly expressed in many human and mouse tissues (25) . DRG1 and DRG2 interact with DFRP1 and DFRP2, respectively (14) , suggesting that they have distinct functions. DRG1 increases its expression during embryonic development (20) , and interacts with SCI (TAL-1) (27) , which is essential for early hematopoietic development (30) and osteoclastogenesis (37) . Conversely, DRG2 is found to be highly expressed in actively growing tissues and the reproductive organs of Arabidopsis thaliana (mouse-ear cress) (8) . Moreover, overexpression of DRG2 caused cell cycle arrest in the G2/M phase (19, 32) . Collectively, these findings suggest that DRG2 may affect differentiation and activity of OCs.
In this study, we investigated the role of DRG2 in in vivo bone remodeling, using DRG2 transgenic (Tg) mice. Our study has focused the action of DRG2 in OCs and demonstrated its contribution to survival and cytoskeleton organization of OCs.
MATERIALS AND METHODS
Animal and OC formation. Two DRG2 Tg lines (45 and 50) were generated (18) , and the genome DNA was extracted from the tail of the mice for genotyping by PCR. To generate DRG2 Tg mice, mouse DRG2 cDNA was placed downstream of the CMV promoter of pcDNA3. The resulting plasmid constructs containing CMV promoter, T7 promoter, mouse DRG2 cDNA, SP6 promoter, and BGH polyA signal was microinjected into male pronuclei of fertilized eggs from superovulated females. Bone marrow cells were isolated from 4-to 5-wk-old DRG2 Tg and wild-type (WT) mice on the background of C57BL/6 mice provided by the Immunomodulation Research Center (IRC), University of Ulsan. All mice were housed in the special pathogen-free animal facility of the IRC, and they were handled in accordance with standards approved by IRC's Institutional Animal Care and Use Committee (IACUC) (2010-023). Femora and tibiae were removed aseptically and dissected free of adherent soft tissue. The bone ends were cut, and the marrow cavity was flushed out with ␣-MEM from one end of the bone, using a sterile 21-gauge needle. The bone marrow was further agitated using a Pasteur pipette to obtain a single-cell suspension, which was washed twice and incubated on plates with M-CSF (20 ng/ml, 416-ML; R&D Systems, Minneapolis, MN) for 16 h. Nonadherent cells were then harvested, layered on a Ficoll-Hypaque gradient, and cultured for two more days, by which time large populations of adherent monocyte/macrophagelike cells had formed on the bottom of the culture plates treated with M-CSF, as previously described (22) . The few nonadherent cells were removed by washing the dishes with phosphate-buffered saline (PBS), and the adherent cells (bone marrow-derived macrophages, BMMs) were harvested using 0.02% EDTA and seeded at 8 ϫ 10 3 cells/well. The adherent cells were analyzed by FACS and found to be negative for CD3 and CD45R and positive for CD11b and F4/80. The absence of contaminating stromal cells was confirmed by lack of cell growth in the absence of M-CSF. Additional medium with M-CSF and RANKL (40 ng/ml, 462-TR; R&D Systems) was added and later refreshed on day 3. After indicated incubation times, the cells were fixed in 10% formalin for 10 min and stained for tartrate-resistant acid phosphatase (TRAP) (33) . The numbers of TRAP-positive multinucleated cells (MNC; i.e., OCs with Ն3 nuclei) were scored. BMM was transfected with small interfering RNA (siRNA) against DRG2 (siDRG2A, sc-143171; Santa Cruz Biotechnology; siDRG2B, GS13495; Qiagen, Hilden, Germany) or scrambled siRNA (scRNA) (sc-37007; Santa Cruz Biotechnology) using Lipofectamine RNAiMAX (13778-075; Invitrogen) and further analyzed. OCs were further assessed for their ability to form pits in dentine slices (17) . Mature OCs were generated by incubation with M-CSF and RANKL from BMMs for 5 days and harvested, using 0.02% EDTA for 20 min followed by replacement with calcium/magnesium-free PBS for scraping cells (10) . To visualize the resorption pits, 1,000 of the cells were seeded on dentine slices and incubated for 1 day with M-CSF and RANKL. The slices were then cleaned by ultrasonication in 1 M NH4OH to remove adherent cells and stained with Mayer's hematoxylin (MHS-16; Sigma Chemical, St Louis, MO).
Micro-CT (CT) scanning was performed using the GE eXplore Locus SP system (Locus SP, GE Healthcare) as described elsewhere (31) . For three-dimensional trabecular architecture of long bone, femurs were scanned with a high-resolution CT imaging system set to a 0.008-mm effective detector pixel size. The software used for three-dimensional microstructure analysis was provided by eXplore MicroView 2.2 software. The following serum markers were measured according to the manufacturer's directions (Immunodiagnostic Systems, Jena, Germany): serum collagen-type I fragments (CTX-1) by RatLaps EIA (AC-06F1), serum TRACP-5b (SB-TR103) by solidphase immunofixed enzyme activity assay, and N-terminal propeptide of type I procollagen (PINP; AC-33F1) by a competitive EIA. For in vivo TRAP-positive OC analysis, mouse femora were excised, cleaned of soft tissue, and decalcified in EDTA. Representative histological sections (paraffin embedded, 4 m thick) of distal femoral metaphysis of WT and DRG2 Tg mice were stained for TRAP to identify OCs that were increased in the DRG2 Tg mice (original magnification ϫ400). Bone histomorphometry was measured using Image Pro Plus 3.0 software (Media Cybernetics). In vivo apoptosis was measured using a TUNEL assay according to the manufacturer's instructions (ApopTag Peroxidase In Situ Detection kit; S7100; Chemicon).
Quantitative PCR. Total RNA was reverse-transcribed using oligo(dT) primer and AMV Reverse Transcriptase (M5101; Promega, Madison, WI), as specified by the manufacturer. qPCR was carried out in a DNA Engine Opticon Continuous Fluorescence Detection System (MJ Research, Waltham, MA), using a QuantiTect SYBR Green PCR kit (204143; Qiagen) and primers specified by the manufacturer. The specificity of each primer pair was confirmed by melting curve analysis and agarose gel electrophoresis. The housekeeping GAPDH gene was amplified as well as the gene of interest. Relative copy numbers compared with GAPDH were calculated using 2
Ϫ⌬⌬CT
. The primer sequences were as follows: DRG2, 5=-ctcgactacctggagat-3= and 5=-acgtcctcatgctccatagt-3=; nuclear factor of activated T cells cytoplasmic1 (or NFAT2), 5=-aataacatgcgagccatcatc-3= and 5=-tcaccctggtgttcttcctc-3=; cathepsin K, 5=-tgaggcttctcttggtgtccatac-3= and 5=aaagggtgtcattactgcggg-3=; calcitonin receptor, 5=-ctgctcctagtgagcccaac-3= and 5=-cagcaatcgacaaggagtga-3=; DC-STAMP, 5=-agacgtggtttaggaatgcagctc-3= and 5=-tcctccatgaacaaacagttccaa-3=; ATP6v0d2, 5=-ttcagttgctatccaggactcgga-3= and 5=-gcatgtcatgtaggtgagaaatgtgctca-3=; GAPDH, 5=-acccagaagactgtggatgg-3= and 5=-cacattgggggtaggaacac-3=.
Apoptosis assay. OC apoptosis was detected by annexin V staining. OCs derived from BMMs stimulated with RANKL for 4 days were washed and incubated without cytokines for 12 h. OCs were harvested by using 0.02% EDTA for 20 min followed by replacing with calcium/magnesium-free PBS for scraping cells, incubated with annexin V-FITC (556419; BD Biosciences, San Jose, CA) in annexin binding buffer (556454; BD Biosciences) for 15 min and immediately analyzed by FACSCalibur.
Western blotting. Cell lysates were prepared and fractionated by SDS-PAGE followed by electroblotting to visualize the phosphorylated and total forms of ERK (9101, 4695; Cell Signaling, Beverly, MA), Akt (4058, 9272; Cell Signaling), ␤-actin (sc-47778; Santa Cruz Biotechnology), and Bim (559685; BD Biosciences). The Active Pull-Down and Detection Kit (Thermo Scientific, Rockford, IL) was used to extract and detect active Rho (89854Y) and Rac1 (89856Y), as specified by the manufacturer.
Actin cytoskeleton. Tibiae were dissected free of soft tissue and sectioned longitudinally. Marrow from the tibiae was imprinted onto glass slides, and the cells were fixed with formaldehyde. To examine the F-actin distribution within OCs, the slides were treated with 0.1% Triton X-100 in PBS for 5 min and stained with rhodamine phalloidin (R415; Molecular Probes, Carlsbad, CA) for actin, and Hoechst 33258 (B-1155; Sigma Chemical) for the nuclei. The cytoplasmic distribution of F-actin was examined using a fluorescence microscope (Carl Zeiss, Germany).
Statistical analysis. All values are expressed as means Ϯ SE. Student's t-test was used to evaluate differences between the samples of interest and their respective controls. Differences between groups were assessed by one-way ANOVA followed by Bonferroni posttests. A P value of Ͻ0.05 was considered statistically significant.
RESULTS

Overexpression of DRG2 decreases bone density by affecting OC-mediated bone resorption in vivo.
To investigate the role of DRG2 in bone remodeling, we analyzed femoral bones from the DRG2 Tg mice and the age-matched WT mice by CT. No significant differences in body size or shape were observed between Tg and WT mice at 10 wk of age (data not shown). Three-dimensional CT scans at the level of the secondary spongia of the distal femur revealed that DRG2 overexpression decreased femoral bone mass in basal conditions (Fig. 1A ). The Tg mice had a significantly lower trabecular bone mineral density (BMD) than the WT mice, with a significant decrease in bone surface-tovolume ratio and trabecular number and a significant increase in trabecular separation (Table 1 ). The increased bone resorption in the Tg mice was confirmed by the finding of elevated serum CTX-1, and increased number of OCs was confirmed by elevation of serum TRACP 5b (Table 1 ). In agreement with this, histological sections of the distal femur also showed a higher number of TRAP-positive OCs in the overexpression of DRG2 (Fig. 1B and Table 1 ). To confirm that this increase was due to the reduced susceptibility of OCs to apoptosis, in vivo TUNEL staining was performed. Overexpression of DRG2 increased the number of TUNEL-negative OCs compared with WT mice in vivo (Fig. 1C) . However, serum marker of bone formation PINP was not significantly affected in the Tg mice (Table 1) . These results suggest that DRG2 overexpression enhances OC-mediated bone resorption, leading to bone loss in vivo.
DRG2 overexpression increases fusion and spreading of OCs and OC survival in vitro. Next, we assessed the biological function of DRG2 in osteoclastogenesis in vitro. We analyzed the expression levels of DRG2 in BMMs and OCs derived from the Tg and WT mice. DRG2 was expressed constitutively in the BMMs, and no significant difference in expression was found between the Tg and the WT BMMs ( Fig. 2A) . DRG2 expression was significantly upregulated during OC differentiation, and it was 1.9-fold higher in the Tg OCs than in the WT cells ( Fig. 2A) .
Since osteoclastogenesis increased the expression of DRG2, we next examined whether DRG2 affected osteoclastogenesis. RANKL induced the formation of TRAP-positive MNCs, which peaked after 3 days of incubation and decreased afterward. The total number of OCs from the WT mice decreased on day 6 of RANKL treatment compared with day 3. However, less decrease was observed in Tg OCs than in WT OCs (Fig.  2B) . As a result, Tg mice (clone 50) had the highest number of OCs (1.8-fold higher than the WT ; Fig. 2B) ; therefore, all further experiments were performed using DRG2 Tg (clone 50). Overexpression of DRG2 (clone 50) significantly increased the number of TRAP-positive MNCs (OCs with Ն3 nuclei) after 3 days of RANKL exposure compared with the WT mice, although the effect was modest (Fig. 2B) . More marked change was number of OCs with Ն15 nuclei (Fig. 2C) . The spreading area of the Tg OCs was also significantly larger than that of the WT OCs when each OC with 15 nuclei was evaluated (Fig. 2C) . Consistently, the transcription of RANKLregulated genes NFAT2, DC-STAMP, ATP6v0d2, cathepsin K, and calcitonin receptor was significantly elevated in the DRG2-overexpressing cells, showing higher levels with clone 50 than with clone 45 (Table 2) .
Since DRG2 overexpression attenuated the decrease of OC numbers after longer exposure to RANKL, we examined whether DRG2 overexpression enhanced OC survival. Differentiated OCs readily undergo apoptosis in the absence of survival factors (21) . As shown in Fig. 2D Values are expressed as means Ϯ SE. DRG2, developmentally regulated GTP-binding protein-2; Tg, transgenic. Trabecular bone mineral density (BMD) measured in right femora. Trabecular bone surface as percentage of bone volume (BS/BV, %). Tb.N., mm, mean number of trabeculae. Tb.Sp., mm, distance between successive trabeculae in distal femora measured on CT images. osteoclast (OC) activity and number were assessed by measuring serum CTX-1 and serum TRACP-5b, respectively. In vivo bone formation was measured by serum PINP. In vivo TRAP staining of the histological section of the distal femur showed that the number of OCs was increased in the Tg (NOC/BS, OC number over total bone surface). In vivo TUNEL staining revealed less apoptotic OC-like cells in DRG2 Tg mice vs. WT mice. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. WT.
To test whether the enhanced OC survival was due to an antiapoptotic effect, we measured the incorporation of annexin V in mature OCs. The fraction of annexin V-positive mature OCs from the Tg mice after cytokine removal was significantly reduced compared with that from the WT cells (Fig. 2E) . To test whether DRG2 affected the proliferation of BMMs, thymidine incorporation was determined, but no significant difference between the Tg and the WT cells was observed (data not shown). . H: mature OCs were incubated for 12 h without cytokine for TRAP counting. Percentage of surviving OCs was calculated from the numbers of TRAP-positive MNCs before washing. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. I: bone marrow stromal cells/osteoblasts (BMSC/OB) (BMSC/OB) at day 0 or day 6 of osteogenic medium from WT and DRG2 Tg mice was harvested to determine mRNA of DRG2. **P Ͻ 0.01. J: WT BMMs (10 4 cells/well) were seeded onto BMSC/OB (10 4 cells) from WT and DRG2 Tg mice. BMSC/OB was isolated by the method of Tropel et al. (34) . Cocultures were treated with 10 nM 1␣,25-dihydroxycholecalciferol (VD3) and 100 nM dexamethazone for 7 days, fed on day 3 by replacing medium, fixed, and stained for TRAP for counting. *P Ͻ 0.05. K: BMSC/OB at day 6 of osteogenic medium was stimulated upon IL-1␣ for 24 h and harvested to determine transcripts of RANKL and osteoprotegerin (OPG)to calculate the ratio of RANKL to OPG. **P Ͻ 0.01. Similar results were obtained in 3 independent experiments.
To confirm the effect of DRG2 in OCs, two different combinations of siDRG2 (siDRG2A and siDRG2B, which were different pools of siRNA) or scRNA were transfected to BMM. Both of the siDRG2's significantly downregulated DRG2 as well as decreased transcript of calcitonin receptor compared with scRNA (Fig. 2F) . Knockdown of DRG2 also reduced the number of large OCs and area fraction occupied by OCs having 15 nuclei (Fig.  2G) . The fraction of OCs survived after cytokine removal was also significantly attenuated by two different combinations of siDRG2 compared with scRNA (Fig. 2H) . Taken together, these results confirmed that DRG2 played a critical role in fusion and spreading of OCs as well as OC survival.
Next, we wondered whether other types of cells besides OCs contributed to in vivo phenotypes observed in bone. We have investigated whether DRG2 overexpression in bone marrow stromal cells/osteoblasts (BMSC/OB) affected osteoclastogenesis. As shown in Fig. 2I , osteogenic condition for 6 days increased the expression of DRG2 in BMSC/OB with 2.6-fold higher in DRG2 Tg cells than WT cells. OC formation was enhanced in coculture system when BMSC/OB was obtained from DRG2 Tg mice compared with that from WT mice (Fig.  2J) . As a functional assessment of BMSC/OB in the overexpression of DRG2, we measured expression of RANKL and osteoprotegerin (OPG) upon IL-1␣ stimulation. The ratio of RANKL to OPG mRNA increased nearly 1.83-fold when DRG2 was overexpressed (Fig. 2K) .
DRG2 increases OC activity via enhancing M-CSF signaling.
The upregulation of fusion and spreading by DRG2 overexpression led us to evaluate the effect of DRG2 on actin organization, since fusion and spreading are functions of the actin cytoskeleton. Actin rings represent the polarized OC cytoskeleton and are signatures of functional OC. To examine in vivo actin organization in OCs, primary OCs prepared directly from the bones of ovariectomized Tg and WT mice were assessed for the presence of actin rings. The cells from the Tg mice formed larger actin rings and contained increased numbers of nuclei compared with the WT OCs (Fig. 3A) , demonstrating that DRG2 enhances the size of functional OCs. To confirm these findings, mature OCs were generated on dentine in vitro to assess for actin ring formation. As shown in Fig.  3B , formation of actin rings in these OCs generated upon M-CSF and RANKL stimulation was induced by incubation with RANKL or/and M-CSF, whereas the OCs incubated with a cytokine-free medium failed to restore actin rings (data not shown). The M-CSF-treated OCs from the Tg mice showed enhanced actin ring formation (lower 2nd column) compared with the similarly treated WT cells (upper 2nd column), whereas no difference was observed upon RANKL stimulation. The difference in the number of OCs with an actin ring between the WT and the Tg cells was significant only in the OCs with Ն6 nuclei (Fig. 3B) . The effect of downregulation of DRG2 by siRNA on actin ring formation was evaluated by mature OCs seeded on glass plates. As shown in Fig. 3C , both of siDRG2 reduced significantly the number of OCs (Ն15 nuclei) having actin rings.
Finally, we turned to the resorptive capacity of OCs from DRG2 Tg mice. To test this idea, we examined the ability of mature OCs to form pits in dentine slices upon M-CSF and RANKL stimulation. Mature OCs from the Tg mice had significantly larger pit areas than the WT OCs (Fig. 3D) , suggesting that DRG2 enhances bone resorption activity. Knockdown of DRG2 using two different combinations of siDRG2 decreased the pit area on dentine slices compared with scRNA (Fig. 3E) , supporting the functional OC activity of DRG2.
Because overexpression of DRG2 enhanced M-CSF-induced cytoskeletal organization in the OCs, we next focused on the signaling pathway mediating this effect. The cytoskeletal structure of OCs is regulated by RhoA and Rac1 in response to M-CSF (6, 36) . Thus, we first assessed the activation of Rac1 and Rho in the M-CSF-treated OCs. Both Rac1 and Rho were rapidly activated at 5 min after M-CSF treatment in both types of OCs; however, the activities of Rac1 and Rho in the Tg OCs were, respectively, 3.27-and 1.68-fold higher than in the WT cells (Fig. 3F) . The observed enhanced OC survival due to DRG2 overexpression raised the question whether DRG2 affects the activation of ERK and Akt, or the expression of the proapoptotic Bim, all of which have been reported to enhance OC survival (1, 4, 28) . M-CSF stimulation resulted in a rapid activation of ERK and Akt after 5 min of treatment followed by a reduction. After 5 min of treatment, phosphorylation of ERK and Akt was elevated in the DRG2-overexpressing cells 2.62-and 2.45-fold, respectively, compared with the WT cells (Fig. 3F) . As shown in Fig. 3E , Bim was induced upon cytokine removal, and M-CSF stimulation decreased the level of Bim in the OCs from both types of mice. However, the level of Bim in the Tg OCs was lower and decreased faster than that in the WT cells.
To determine whether these enforced signals could be involved in the DRG2-mediated increase in the number of large OCs with actin rings, we treated the cells with pharmacological inhibitors of each of the signaling proteins: Rac1, Rho, Akt, or ERK. As shown in Fig. 3G , all of the inhibitors reduced the number of large OCs (Ն15 nuclei) with actin rings, and blockade of Rac1, Rho, Akt, or ERK completely abolished the effect of DRG2 on the number of large OCs with actin rings, suggesting that DRG2 contributes to the fortification of M-CSF-mediated signaling pathways that are associated with cytoskeleton organization.
DISCUSSION
DRG2 has been found to be a novel member of the GTPbinding protein family, but its role is largely unknown. We found that DRG2 Tg mice suffered significant bone loss compared with WT mice under physiological conditions. The DRG2 Tg mice showed reduced trabecular BMD, an endpoint parameter in the assessment of bone mass, along with decreased bone surface and trabecular number and increased trabecular distance, suggesting Values are expressed as means Ϯ SE. BMMs were incubated with M-CSF (20 ng/ml) and RANKL (40 ng/ml) to induce OC differentiation. After 48 h, total RNA was extracted and analyzed to determine fold change of mRNA levels for NFAT2, cathepsin K, calcitonin receptor, DC-STAMP, and ATP6v0d2. Expression levels before RANKL treatment were set at 1. *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. WT. ND, not determined. that DRG2 plays a critical role in bone remodeling. Serum levels of TRACP-5b and CTX-1 were higher in the Tg mice, whereas no significant difference was found in PINP, an in vivo bone formation marker. Additionally, in vitro bone resorption on dentine slices was higher in the Tg OCs than in WT OCs. These data suggested that the observed bone loss was at least partly due to increased OC-mediated bone resorption.
Clinical prediction of bone fracture risk primarily depends on measurement of BMD, although it is not absolutely dependent on bone's resistance to cracking. However, biomechanically tested in a fall simulation, radial bone strength has been shown to be highly correlated with a combination of BMD and trabecular structural measurements (2) . In addition, high levels of bone turnover markers are demonstrated to be effective in predicting fracture risk (35) . Although we have not determined biomechanical strength to predict bone fragility in the overexpression of DRG2, it is possible to predict that overexpression of DRG2 results in fragile bone from decreased BMD, BS/BV (bone surface/bone volume), and Tb.N. (trabecular number), and increased Tb.Sp. (trabecular separation), serum TRACP5b, and serum CTX-1.
Previous reports suggest that DRG2 plays a critical role in the growth and differentiation of cells (19, 32) . It is possible that DRG2 modulates the differentiation of OCs, leading to the increased bone resorption and loss observed in the Tg mice. Overexpression of DRG2 increased the number of OCs by elevating OC survival, suggesting that DRG2 affects the pace at which mature OCs undergo apoptosis. Interestingly, DRG2 overexpression led to a large OC due to elevated fusion and spreading, resulting in elevated bone resorption. Consistently, the transcripts of OC fusion markers DC-STAMP and ATP6v0d2and functional OC markers cathepsin K and calcitonin receptor were elevated significantly in OCs of DRG2 Tg mice. These findings suggest that the greater bone resorption in the Tg cells was due to enhanced number of OCs as well as OC activity, e.g., as a result of the increased numbers of large OCs with actin rings, which are associated with M-CSF signaling. Since actin rings are critical for OC-mediated bone resorption (5), and multinucleated OCs are much more efficient at resorption than their mononuclear counterparts (13) , it is likely that the increase in the number of large OCs with actin rings contributed to the bone loss we observed in the Tg mice. The role of DRG2 was further confirmed by knockdown of DRG2 using siDRG2A. Decreased DRG2 expression resulted in lowering the number of OCs that were larger and contained more nuclei, decreased OC survival, and impaired bone resorption. A similar pattern was observed with siDRG2B, which had different combinations of siDRG2 from siDRG2A, supporting the results from knockdown experiments. Further studies using DRG2 knockout mice are under investigation. Our finding showed that DRG2 decreased the expression of Bim, thus protecting mature OCs from the apoptosis expected in the absence of cytokines (1) . Improved OC survival also supports elevated bone resorption observed in the Tg mice.
Overexpression of DRG2 was more prominent in OCs than in BMMs, suggesting that RANKL provides a more favorable microenvironment to maintain its overexpression. It is possible that CMV enhancer-promoter activation in RANKL-stimulated cells may be due to the activation of transcription factor NF-B, given that NF-B recognition sites do exist in the CMV enhancerpromoter sequence and can be bound by NF-B, resulting in transcriptional activation. A similar finding was observed in mouse liver (26) . The cellular defect in OCs appeared to be less than the phenotype observed in vivo, implying that the possibility that overexpression of DRG2 in other cells may affect bone metabolism. Osteogenic induction increased the expression of DRG2. Coculture with BMMs and BMSC/OB showed that BMSC/OB from DRG2 Tg mice enhanced TRAP-positive MNCs, at least partly, via increasing the ratio of RANKL/OPG. This result suggested that observed bone loss through increased number of OCs could be due to BMSC/OB as well as OCs. Since an in vivo bone formation marker, PINP, was not significantly elevated in the Tg mice, it is possible that DRG2 modulates BMSC/OB to enhance osteoclastogenesis without affecting OB differentiation.
Small GTPases are known to control OC activity (6, 15, 16, 36) . The Rho family controls the cytoskeletal organization, which is critical for functional OCs under the influence of M-CSF (6). Rac1 is known to regulate the actin cytoskeleton and cell-cell fusion (7) . The absence of Rac1 attenuates M-CSF-stimulated membrane ruffling and migration (36) . Rac is also known to mediate antiapoptotic signals in hematopoietic cells (29) and to be required for OC survival, mainly through the PI3K/Akt signaling pathway activated by M-CSF (4). Thus, we hypothesize that DRG2 increases OC bone resorption by enhancing the activity of small GTPases. In line with this hypothesis, DRG2 overexpression enhanced the activity of Rac1 and Rho, whereas inhibitors of Rac1 and Rho abolished the effects of DRG2 on OC function. However, it is not clear how DRG2 affects the activities of these GTPases. Previous studies have reported that small GTPases mediate M-CSF and/or RANKL signaling in OCs by modulating the PI3K/Akt and ERK pathways (4, 15) . We found that phosphorylation of Akt and ERK increased in the OCs that overexpressed DRG2. Moreover, blockade of Rac1, Rho, ERK, or Akt abolished the DRG2-associated increase in the number of large OCs with actin rings, indicating that DRG2 is involved in reorganization of cytoskeleton through a Rac1/Rho/ERK/Aktdependent signaling pathway.
In conclusion, this is the first study to demonstrate a role of DRG2 in osteoclast biology. This novel study provides the evidence that DRG2 strengthens M-CSF-stimulated survival and cytoskeleton organization involving fusion and spreading of OCs and results in bone loss through enhanced bone resorption by OCs, although the molecular mechanisms responsible for this Fig. 3 . Overexpression of DRG2 increases OC activity by enhancing M-CSF signaling. A: marrow from ovariectomized WT and DRG2 Tg tibiae was blotted onto glass slides. Cells were fixed with formaldehyde, incubated with 0.1% Triton X-100 in PBS for 5 min and stained with rhodamine-phalloidin and Hoechst. OCs were defined as cells with Ͼ3 nuclei surrounded by actin rings. Scale bar, 20 m. Relative sizes of OCs with actin rings were determined using ImageJ 1.37v software. *P Ͻ 0.05. B: BMMs were loaded onto dentine and cultured with M-CSF and RANKL. After 5 days, mature OCs were washed and stimulated with medium (vehicle), M-CSF (20 ng/ml), RANKL (40 ng/ml), or M-CSF ϩ RANKL for 5 h. Representative photos are shown for each condition. Scale bar, 50 m. Frequency distribution of OCs according to numbers of nuclei. Tg OCs with Ն6 nuclei differed significantly from WT OCs in response to M-CSF or the combination of M-CSF and RANKL. **P Ͻ 0.01. C: BMMs were transfected with 2 different siDRG2 or scRNA. Mature OCs were removed with EDTA, washed, seeded on glass coverslips, and stimulated with M-CSF ϩ RANKL for 5 h. Frequency distribution of OCs transfected with each siRNA according to numbers of nuclei. OCs (Ն15 nuclei) transfected with siDRG2A or siDRG2B differed significantly from OCs with scRNA. **P Ͻ 0.01, ***P Ͻ 0.001. D: mature OCs from WT and DRG2 Tg mice were incubated on whole dentine slices in the presence of M-CSF and RANKL for 1 day, and slices were stained with Mayer's hematoxylin. Representative photos of resorption pits from WT and DRG2 Tg OCs are shown (magnification, ϫ20). Scale bar, 50 m. The resorption pit area was determined using ImageJ 1.37v software. *P Ͻ 0.05. E: resorption pits from siDRG2A and siDRG2B-transfected cells differed significantly from scRNA-transfected OC. ***P Ͻ 0.001. F: cytokine-and serum-starved mature OCs from WT and DRG2 Tg mice were stimulated with M-CSF (100 ng/ml). GTP-Rac1 and GTP-Rho were isolated by GST pull-down and immunoblotted with Rac1-and Rho-specific Abs. For Rac1 and Rho, lysates (500 g each) were subjected to a Rac1-GTP pull down assay with GST-Pak1-Rac1 binding domain and a Rho-GTP pull down assay with GST-Rhotekin-Rho binding domain, respectively, following manufacturer's protocol. Phosphorylated and total ERK and Akt were determined by Western blotting. Western blotting using Bim-specific Ab was performed to visualize Bim expression in OCs after 4 h of vehicle (V) or M-CSF (M) stimulation. Numbers above bands indicate ratio of intensity relative to corresponding total form (Rac1, Rho, ERK, Akt) or ␤-actin. effect remain to be identified. Since cytoskeletal reorganization associated with osteoclastogenic fusion and spreading plays a critical role in bone resorption, its modulation through DRG2 may help to identify novel pharmacological approaches to inhibit excess bone loss or to accelerate bone degradation when required. 
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